Table 1.
Main-duct IPMNs (n = 81) | Combined IPMNs (n = 149) | Branch-duct IPMNs (n = 159) | P value, main-duct vs combined | P value, main-duct vs branch- duct | P value, combined vs branch-duct | |
---|---|---|---|---|---|---|
Median age, y (range) | 67 (37–85) | 66 (31–87) | 66 (35–90) | .7 | .9 | .7 |
Sex (%) | ||||||
Female | 36 (44.5) | 66 (44) | 91 (57) | .5 | .04 | .01 |
Male | 45 (55.5) | 83 (56) | 68 (43) | |||
Family history of pancreatic cancer (%) | ||||||
Yes | 6 (7.5) | 12 (8) | 16 (11) | .5 | .2 | .2 |
No | 75 (92.5) | 137 (92) | 126 (89) | |||
History of other neoplasm (%) | ||||||
Yes | 18 (22) | 29 (19.5) | 32 (20) | .3 | .4 | .4 |
No | 63 (78) | 120 (80.5) | 127 (80) | |||
Tumor site (%) | ||||||
Proximal | 52 (64) | 100 (67) | 82 (52) | .7 | .4 | .1 |
Distal | 26 (32) | 34 (23) | 40 (25) | .1 | .6 | .3 |
Diffuse | 3 (4) | 15 (10) | 37 (23) | .1 | .0001 | .003 |
Entire pancreas along MPD | 3 (4) | 15 (10) | 0 | |||
Multifocal lesions | 0 | 0 | 37 (23) | |||
Incidental diagnosis (%) | ||||||
Yes | 11 (13.5) | 28 (19) | 55 (34.5) | .2 | .0001 | .001 |
No | 70 (86.5) | 121 (81) | 104 (65.5) | |||
Abdominal pain (%)a | ||||||
Yes | 45 (53) | 88 (59) | 72 (45) | .2 | .1 | .1 |
No | 38 (47) | 61 (41) | 87 (55) | |||
Presence of other symptoms (%)a | ||||||
Yes | 59 (73) | 89 (60) | 72 (45) | .032 | .0001 | .008 |
No | 22 (27) | 60 (40) | 87 (65) | |||
Jaundice | 14 (17) | 25 (17) | 7 (5) | .5 | .001 | .001 |
Diabetes | 10 (12) | 16 (11) | 14 (9) | .4 | .2 | .3 |
Weight loss | 41 (50.5) | 60 (40) | 37 (23) | .08 | .0001 | .001 |
Acute pancreatitis | 14 (17) | 17 (11.5) | 27 (17) | .1 | .5 | .1 |
Pathology (%) | ||||||
Adenoma | 9 (11) | 12 (8) | 71 (44) | .5 | .0001 | .0001 |
Borderline | 17 (21) | 45 (30) | 54 (34) | .1 | .05 | .5 |
Carcinoma in situ | 16 (20) | 30 (20) | 17 (11) | .9 | .08 | .03 |
Invasive carcinoma | 39 (48) | 62 (42) | 17 (11) | .4 | .0001 | .0001 |
Presence of lymph node metastases (%)b | 13 (33) | 30 (48.5) | 4 (23.5) | .09 | .3 | .05 |
Some patients complained of more than 1 symptom.
Rate of lymph node metastases was calculated considering only patients with invasive cancer.